[Migraine therapy].
With more than 8 million sufferers in Germany alone, migraine is one of the most frequent medical disorders. Recent discoveries in the pathophysiology and genetics of headaches, as well as specific developments in pharmacology, have paved the way for a significant improvement in both acute migraine treatment and migraine prevention. Within the group of 5-HT(1B/D)-agonists (triptans), seven substances with 23 dosages and formulations have been approved in Germany that allow the customized treatment of migraine attacks. In addition, several new drugs such as valproic acid or topiramate are now available as drugs of first choice for migraine prevention, as well as the well established beta blockers, thus enabling the physician to tailor the preventative treatment according to the individual needs of the patient.
Universitätsklinik für Neurologie, Essen. h.diener@uni-essen.de
H-C
HC
Diener
V
V
Limmroth
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D000077236:Topiramate; D014363:Tryptamines / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D012702:Serotonin Antagonists; D014363:Tryptamines; D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid